JP2025521231A5 - - Google Patents
Info
- Publication number
- JP2025521231A5 JP2025521231A5 JP2024572421A JP2024572421A JP2025521231A5 JP 2025521231 A5 JP2025521231 A5 JP 2025521231A5 JP 2024572421 A JP2024572421 A JP 2024572421A JP 2024572421 A JP2024572421 A JP 2024572421A JP 2025521231 A5 JP2025521231 A5 JP 2025521231A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210639331.4 | 2022-06-08 | ||
| CN202210639331 | 2022-06-08 | ||
| PCT/CN2023/098753 WO2023236971A1 (zh) | 2022-06-08 | 2023-06-07 | Cd73抗体鸡尾酒疗法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025521231A JP2025521231A (ja) | 2025-07-08 |
| JP2025521231A5 true JP2025521231A5 (cg-RX-API-DMAC10.html) | 2026-05-20 |
Family
ID=89117604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024572421A Pending JP2025521231A (ja) | 2022-06-08 | 2023-06-07 | Cd73抗体カクテル療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20260217849A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4538289A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025521231A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20250023471A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119403832A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3258260A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TW202405018A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023236971A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| WO2017118613A1 (en) * | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| AU2017228470A1 (en) * | 2016-03-04 | 2018-08-30 | Bristol-Myers Squibb Company | Combination therapy with anti-CD73 antibodies |
| EP4058150A2 (en) * | 2019-11-15 | 2022-09-21 | Genzyme Corporation | Biparatopic cd73 antibodies |
| JP2023546743A (ja) * | 2020-10-23 | 2023-11-07 | 中山康方生物医▲藥▼有限公司 | 抗cd73抗体及びその使用 |
| TWI900705B (zh) * | 2020-12-11 | 2025-10-11 | 大陸商上海華奧泰生物藥業股份有限公司 | Cd73的抗原結合蛋白及其應用 |
| US20240067747A1 (en) * | 2021-01-13 | 2024-02-29 | Shanghai Huaota Biopharmaceutical Co., Ltd. | Cd73-binding protein and use thereof |
-
2023
- 2023-06-07 WO PCT/CN2023/098753 patent/WO2023236971A1/zh not_active Ceased
- 2023-06-07 EP EP23819136.5A patent/EP4538289A4/en active Pending
- 2023-06-07 US US18/872,421 patent/US20260217849A1/en active Pending
- 2023-06-07 KR KR1020257000422A patent/KR20250023471A/ko active Pending
- 2023-06-07 CA CA3258260A patent/CA3258260A1/en active Pending
- 2023-06-07 TW TW112121274A patent/TW202405018A/zh unknown
- 2023-06-07 CN CN202380045319.3A patent/CN119403832A/zh active Pending
- 2023-06-07 JP JP2024572421A patent/JP2025521231A/ja active Pending